Gilead victory defines competitiveness landscape in India
This article was originally published in Scrip
Executive Summary
In deciding that Gilead Sciences was not anticompetitive in India’s HIV/AIDS market, India’s monopoly authority has done more than help clear the company’s good name. It has described what a competitive market looks like. And, reading the finer print of its judgment, it seems also to be saying that goodwill and products of the future play little part in the bald reckoning that underlies its competitiveness calculus.